Intelligent Bio Solutions

Intelligent Bio Solutions Working Capital Turnover

The Working Capital Turnover of Intelligent Bio Solutions (INBS) as of Oct 21, 2026 is 3.03. In the previous year, Working Capital Turnover was -3.14 — a change of -196.50% (higher).

Working Capital Turnover

3.03

YoY

-196.50%

Last updated:

Working Capital Turnover of Intelligent Bio Solutions is 2026 3.03 . Working Capital Turnover of Intelligent Bio Solutions was 2025 -3.14 . It decreases by -196.50% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligent Bio Solutions Stock analysis

What does Intelligent Bio Solutions do? Intelligent Bio Solutions, Inc. generates revenue through its Commercially available Intelligent Fingerprinting Products (IFPG) segment, which includes a portable drug screening system analyzing fingerprint sweat via a one-time cartridge and handheld reader. The company also develops diagnostic tests under the Development Stage Saliva Glucose Biosensor Platform (SGBP), targeting diabetic patients with a non-invasive saliva glucose biosensor (SGB) intended to replace finger-prick blood monitoring. Its biosensor platform supports multiple biological analyte detection for point-of-care diagnostic tests (POCT) in clinical chemistry, immunology, tumor markers, allergens, and endocrinology. The firm serves primary health practitioners and patients seeking non-invasive monitoring solutions. The company's product portfolio features the IFPG segment's portable drug screening system, which is sold to healthcare providers and law enforcement agencies for rapid drug testing. The SGBP segment focuses on developing the Saliva Glucose Biosensor (SGB), a point-of-care diagnostic test expected to address the needs of diabetic patients requiring frequent glucose monitoring without invasive procedures. The biosensor platform enables detection of multiple analytes, expanding the company's offerings in clinical chemistry and related diagnostic fields. Intelligent Bio Solutions, Inc. targets primary health practitioners and patients as key segments for its non-invasive diagnostic solutions. The IFPG segment's portable drug screening system is designed for use in clinical and law enforcement settings, while the SGBP segment's Saliva Glucose Biosensor aims to provide a convenient alternative to traditional blood glucose monitoring for diabetic patients. The company's development stage products focus on replacing invasive methods with real-time, non-invasive monitoring technologies. Intelligent Bio Solutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intelligent Bio Solutions stock

Working Capital Turnover of Intelligent Bio Solutions is 3.03 in 2026.

Working Capital Turnover of Intelligent Bio Solutions changed from -3.14 to 3.03, representing a -196.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Turnover Intelligent Bio Solutions since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's Intelligent Bio Solutions with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Intelligent Bio Solutions

All Key Metrics — Intelligent Bio Solutions